For the treatment of urothelial carcinoma with PARP inhibitors, there are several clinical trials ongoing that investigate Olaparib as monotherapy or in combination with, for example, immune checkpoint inhibitors [49]. This evidence concerns the gene PARP1 and urothelial carcinoma.